Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics RegisterCitation formats

  • External authors:
  • Yvonne King
  • Gabriel Panayi
  • David G I Scott
  • Andrew Bamji
  • Deborah Bax

Standard

Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. / Verstappen, Suzanne M M; King, Yvonne; Watson, Kath D.; Symmons, Deborah P M; Hyrich, Kimme L.; Panayi, Gabriel; Scott, David G I; Bamji, Andrew; Bax, Deborah.

In: Annals of the rheumatic diseases, Vol. 70, No. 5, 05.2011, p. 823-826.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Verstappen, Suzanne M M ; King, Yvonne ; Watson, Kath D. ; Symmons, Deborah P M ; Hyrich, Kimme L. ; Panayi, Gabriel ; Scott, David G I ; Bamji, Andrew ; Bax, Deborah. / Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. In: Annals of the rheumatic diseases. 2011 ; Vol. 70, No. 5. pp. 823-826.

Bibtex

@article{b0ee3cd27c4140f1b3efe12fc17e51ab,
title = "Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register",
abstract = "Objective: The British Society for Rheumatology Biologics Register (BSRBR) has collected data on adverse events including pregnancies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor (anti-TNF) therapy. The purpose of this report is to summarise the pregnancy outcomes in women treated with anti-TNF in the BSRBR. Methods: Patients were categorised according to anti-TNF exposure as follows: (1) exposure to anti-TNF and to methotrexate (MTX) and/or leflunomide (LEF) at conception (n=21 pregnancies); (2) exposure to anti-TNF at conception (n=50); (3) exposure to anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (control group; n=10). Results: Eighty-eight live births in a total of 130 pregnancies were reported in patients who received anti-TNF before or during pregnancy. The rate of spontaneous abortion was highest among patients exposed to anti-TNF at the time of conception (with MTX/LEF 33% and without MTX/LEF 24%). This compared with 17% spontaneous abortions in those with prior exposure to anti-TNF and 10% spontaneous abortions in the control group. Ten terminations were performed. Conclusion: Although the results to date have been promising, no firm conclusions can be drawn about the safety of anti-TNF during pregnancy and, without further evidence, guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed.",
author = "Verstappen, {Suzanne M M} and Yvonne King and Watson, {Kath D.} and Symmons, {Deborah P M} and Hyrich, {Kimme L.} and Gabriel Panayi and Scott, {David G I} and Andrew Bamji and Deborah Bax",
year = "2011",
month = may,
doi = "10.1136/ard.2010.140822",
language = "English",
volume = "70",
pages = "823--826",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ ",
number = "5",

}

RIS

TY - JOUR

T1 - Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

AU - Verstappen, Suzanne M M

AU - King, Yvonne

AU - Watson, Kath D.

AU - Symmons, Deborah P M

AU - Hyrich, Kimme L.

AU - Panayi, Gabriel

AU - Scott, David G I

AU - Bamji, Andrew

AU - Bax, Deborah

PY - 2011/5

Y1 - 2011/5

N2 - Objective: The British Society for Rheumatology Biologics Register (BSRBR) has collected data on adverse events including pregnancies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor (anti-TNF) therapy. The purpose of this report is to summarise the pregnancy outcomes in women treated with anti-TNF in the BSRBR. Methods: Patients were categorised according to anti-TNF exposure as follows: (1) exposure to anti-TNF and to methotrexate (MTX) and/or leflunomide (LEF) at conception (n=21 pregnancies); (2) exposure to anti-TNF at conception (n=50); (3) exposure to anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (control group; n=10). Results: Eighty-eight live births in a total of 130 pregnancies were reported in patients who received anti-TNF before or during pregnancy. The rate of spontaneous abortion was highest among patients exposed to anti-TNF at the time of conception (with MTX/LEF 33% and without MTX/LEF 24%). This compared with 17% spontaneous abortions in those with prior exposure to anti-TNF and 10% spontaneous abortions in the control group. Ten terminations were performed. Conclusion: Although the results to date have been promising, no firm conclusions can be drawn about the safety of anti-TNF during pregnancy and, without further evidence, guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed.

AB - Objective: The British Society for Rheumatology Biologics Register (BSRBR) has collected data on adverse events including pregnancies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor (anti-TNF) therapy. The purpose of this report is to summarise the pregnancy outcomes in women treated with anti-TNF in the BSRBR. Methods: Patients were categorised according to anti-TNF exposure as follows: (1) exposure to anti-TNF and to methotrexate (MTX) and/or leflunomide (LEF) at conception (n=21 pregnancies); (2) exposure to anti-TNF at conception (n=50); (3) exposure to anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (control group; n=10). Results: Eighty-eight live births in a total of 130 pregnancies were reported in patients who received anti-TNF before or during pregnancy. The rate of spontaneous abortion was highest among patients exposed to anti-TNF at the time of conception (with MTX/LEF 33% and without MTX/LEF 24%). This compared with 17% spontaneous abortions in those with prior exposure to anti-TNF and 10% spontaneous abortions in the control group. Ten terminations were performed. Conclusion: Although the results to date have been promising, no firm conclusions can be drawn about the safety of anti-TNF during pregnancy and, without further evidence, guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed.

U2 - 10.1136/ard.2010.140822

DO - 10.1136/ard.2010.140822

M3 - Article

C2 - 21362710

VL - 70

SP - 823

EP - 826

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

SN - 0003-4967

IS - 5

ER -